Gerresheimer (ETR:GXI) Stock Price Down 3.2% - Time to Sell?

Key Points

• Gerresheimer AG shares fell by 3.2%, trading at €42.00 ($48.84) after hitting a low of €41.74 ($48.53) during the day.
• The company has a market capitalization of $1.45 billion and a P/E ratio of 12.71, indicating its valuation relative to earnings.
• Gerresheimer operates in medicine packaging and drug delivery across three divisions, with products including prefillable syringes and inhalers.

Gerresheimer AG (ETR:GXI - ) shares were down 3.2% during trading on Monday . The company traded as low as €41.74 ($48.53) and last traded at €42.00 ($48.84). Approximately 319,353 shares changed hands during trading, an increase of 127% from the average daily volume of 140,925 shares. The stock had previously closed at €43.38 ($50.44).

Gerresheimer Stock Performance

The stock has a market capitalization of $1.45 billion, a P/E ratio of 12.71, a P/E/G ratio of 0.82 and a beta of 0.94. The stock has a 50 day moving average of €49.00 and a 200 day moving average of €61.06. The company has a debt-to-equity ratio of 87.94, a quick ratio of 0.40 and a current ratio of 0.80.

Gerresheimer Company Profile

Gerresheimer AG, together with its subsidiaries, manufactures and sells medicine packaging, drug delivery devices, and solutions in Germany and internationally. It operates through three divisions: Plastics & Devices, Primary Packaging Glass, and Advanced Technologies. The company offers prefillable syringes, plastic and glass packaging solutions, vials, glass cartridges and ampoules, bottles and containers, and glass bottles and jars, as well as caps, closures, applicators, and accessories; development, industrialization and contract manufacturing of drug delivery programs; project and quality management; and drug delivery systems, including inhalers, injection/auto injectors, pen injectors, infusion systems, and inhalation assessment, autoinjector, and other services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.